Микрозер

Quick links to important sections

Микрозер

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Микрозер

Property Description
Active Ingredient Betahistine
Form Tablet
Pharmacological Class Histamine Analogue / Antivertigo Agent
General Purpose Vestibular System Modulator
Origin Synthetic Compound

Микрозер (Mikrozer) is a prescription-only medicine primarily classified as an Antivertigo agent and a Histamine analogue, specifically designed to address disturbances within the inner ear. The medicine is a synthetic compound that functions as a Vestibular system modulator, focusing its therapeutic action on balance and equilibrium mechanisms. Its high-level pharmacological class is defined by its ability to interact with the body's histamine receptors, distinguishing it from general sedatives and non-specific motion sickness remedies. This action is clinically recognized for its efficacy in managing severe dizziness.


Composition, Origin, and Pharmaceutical Form

The active ingredient in Микрозер is Betahistine, chemically synthesized as Betahistine dihydrochloride. The drug is manufactured as a single-ingredient product, which ensures that all observed effects are directly attributable to the specific action of this Histamine analogue. Микрозер is supplied in the high-level dosage form of a tablet for oral administration. The origin/type is strictly a synthetic compound, contrasting with substances derived from natural sources, and the composition includes the active drug combined with an inert solid oral vehicle base necessary for tableting.


What Is the General Purpose of Микрозер?

The general purpose of Микрозер is to help stabilize and correct the underlying physiological issues contributing to balance disorders and symptomatic dizziness. The drug's core benefit is its ability to influence local microcirculation, leading to increased cochlear and cerebral blood flow and assisting in Pressure Management within the labyrinth of the inner ear. The drug's action includes an effect on inner ear fluid dynamics. This action is intended to modulate the system responsible for balance, offering a targeted approach to relieve the feeling of spinning (vertigo).

What side effects are possible with Микрозер?

Possible Side Effects and Safety Information

The safety profile for Микрозер (Betahistine) is officially documented by regulatory agencies and organized by the organ systems affected and the frequency of occurrence.


Documented Adverse Reactions

The most frequently reported adverse reactions are classified as Common, affecting between 1 in 10 and 1 in 100 users. These effects are primarily linked to the Nervous system disorders and Gastrointestinal disorders categories.

Classification Affected System(s) Specific Reaction(s)
Common Nervous system disorders Headache
Common Gastrointestinal disorders Nausea, Dyspepsia, Stomach pain, Abdominal distension
Frequency Not Known Immune & Skin disorders Hypersensitivity reactions (including Anaphylaxis), Angioedema, Rash, Urticaria, Pruritus

Serious Reactions and Constraints

Severe Hypersensitivity reactions, such as Anaphylaxis and Angioedema (swelling of the face, lips, or throat), are documented as serious adverse reactions, although their precise frequency is not known. These reactions fall under the Immune system disorders classification.

Official labeling imposes specific safety constraints. The medicine is Contraindicated in individuals with a phaeochromocytoma, a rare tumor of the adrenal gland. Furthermore, patients with a history of peptic ulcer or those with bronchial asthma require specific consideration during treatment. Gastrointestinal complaints may be lessened by taking the medicine with food. The concomitant use of the drug with certain Antihistamines is noted in regulatory texts due to potential pharmacological conflict.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Микрозер (Betahistine) by listing documented clinical manifestations and required emergency actions. Overdoses up to 640 mg are typically associated with mild to moderate symptoms, including nausea, somnolence (sleepiness), abdominal pain, vomiting, and dyspepsia. Other manifestations noted in official labeling include dry mouth and ataxia (lack of coordination).

More severe systemic outcomes have been reported following the intake of very high doses, particularly in cases of intentional overdose or co-ingestion with other medicinal products. These serious complications involve the central nervous system, heart, and lungs, encompassing convulsions (seizures), as well as pulmonary and cardiac complications.

Because no specific antidote is known for Betahistine, regulatory authorities mandate that overdose management must be symptomatic and supportive. Procedural measures such as gastric lavage may be considered within one hour of ingestion.

Emergency response is strictly required: Regulators state that individuals who suspect or confirm an overdose must seek immediate medical attention. This includes contacting a doctor, hospital emergency department, or a regional Poison Control Centre immediately, even if discomfort or poisoning symptoms have not yet appeared.

Therapeutic Uses of Микрозер

Indications for Use

Микрозер is primarily used for the symptomatic treatment of vestibular disorders. Its application is focused on managing conditions related to the inner ear and the vestibular system, which is responsible for maintaining balance and spatial orientation.

Meniere's Disease

The medication is frequently prescribed for Meniere's disease, a chronic disorder of the inner ear. It addresses the core triad of symptoms associated with this condition:

  • Vertigo: Recurrent episodes of a spinning sensation, often accompanied by nausea or vomiting.
  • Tinnitus: The perception of ringing, buzzing, or other noises in the ear when no external sound is present.
  • Hearing Loss: Progressive or fluctuating sensorineural hearing impairment.

Vestibular Vertigo

Beyond Meniere's disease, Микрозер is used to treat various forms of vestibular vertigo. These are conditions where the patient experiences a false sense of motion or dizziness due to dysfunction in the peripheral vestibular apparatus. It helps in reducing the frequency and intensity of these dizzy spells, improving the patient's ability to perform daily activities.

Therapeutic Benefits

The therapeutic objective of Микрозер is to improve the microcirculation within the inner ear. By acting on the histamine receptors in the vessels of the internal ear, the medication helps to:

  • Reduce Endolymphatic Pressure: It is thought to facilitate the drainage of fluid (endolymph) in the inner ear, which relieves the pressure that causes dizziness and hearing issues.
  • Improve Blood Flow: By enhancing local blood circulation in the stria vascularis, the medication supports the functional recovery of the vestibular system.
  • Facilitate Compensation: It may assist the brain in adapting to imbalances in signals coming from the vestibular organs, leading to a faster recovery of equilibrium.

Eligibility and Restrictions for Use

Who Can and Cannot Use Микрозер? — Official Regulatory Information

This section outlines patient eligibility and non-eligibility strictly based on authoritative regulatory documentation, such as the official Summary of Product Characteristics (SmPC) or Prescribing Information.

Eligibility Scope

Classification Regulatory Statement (Official Labeling)
Populations for whom use is contraindicated Individuals with known hypersensitivity to the active substance or any listed excipients are formally prohibited from using this medicine. Use may also be prohibited in the presence of specific severe, pre-existing conditions (e.g., severe organ dysfunction) as detailed in the official label's Contraindications section.
Age-related eligibility rules Use in the pediatric population (e.g., children under a specified age) is typically not established or officially not recommended due to insufficient data or documented risks to development.
Pregnancy and lactation eligibility status Use during pregnancy and breastfeeding is frequently classified as contraindicated or not recommended due to documented regulatory concerns regarding potential fetal or infant harm.
Condition-specific eligibility rules Patients with documented severe hepatic impairment or severe renal impairment may be excluded or require conditional use due to the drug’s metabolic or excretion characteristics.

Resulting Eligibility Structure

Official regulatory documents define who can and cannot use the medicine by first establishing absolute prohibitions (Contraindications) based on allergy or high-risk comorbidities. The label then sets conditional use rules for special populations (such as specific age groups, pregnant women, and patients with organ impairment) where use is restricted or requires explicit attention to comply with the official safety profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Betahistine (the active substance in Микрозер) defines specific pharmacokinetic and pharmacodynamic interactions.

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions H1 Antihistamines and Monoamine Oxidase (MAO) Inhibitors
Specific interacting medicines (if explicitly listed) Selegiline (an MAO-B selective inhibitor)
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic Competition ( H1 antagonists) and Enzyme-Mediated Metabolic Inhibition (MAO inhibitors)
Timing-based interaction rules (if applicable) None documented. Official labeling does not specify mandatory time separation.
Population-specific interaction notes (if applicable) None documented.
Interaction-related restrictions Co-administration with MAO Inhibitors requires caution. Co-administration with H1 Antihistamines is restricted in some territories due to potential reduction of efficacy.

Interaction Classifications (High-Level)

Classification Official Regulatory Statement
Interaction severity classification Contraindicated/Avoid combination (for H1 Antihistamines in some labels) and Use with Caution/Monitoring Required (for MAO Inhibitors).
Regulatory basis Based on regulatory documents aligned with the European Medicines Agency (EMA) and national health authorities.
Interaction-context constraints Food intake is noted to slow the rate of absorption (Cmax is lower), though the overall extent of exposure (AUC) is similar to the fasted state.

Resulting Interaction Structure

Official Interaction Statements:

  • Co-administration with H1 Antihistamines may result in a reduction of pharmacological effects of either medicine due to pharmacodynamic competition.
  • Monoamine Oxidase Inhibitors are documented to inhibit the metabolism of Betahistine, potentially leading to increased plasma exposure.
  • Regulatory data confirm that no in vivo inhibition of major Cytochrome P450 enzymes by Betahistine is expected.

Connection to the overall interaction profile:

The regulatory profile is defined by a pharmacodynamic restriction concerning H1 antihistamines and a metabolic caution regarding MAO inhibitors, which may increase systemic exposure. The profile contains a further note that the rate of absorption is altered by food intake, though total systemic exposure remains unchanged. This structure strictly focuses on enzyme-mediated and competitive constraints.

Mechanism of Action

How Микрозер Works: Mechanism of Action

Микрозер exerts its pharmacologic effects primarily through modulation of receptor-mediated signaling within specific cellular systems. The compound functions by interacting with targeted receptors to initiate or suppress downstream signaling cascades that are driven by distinct transmitters or mediators. This interaction modifies early molecular steps, fundamentally altering the activity profile of the involved pathways.

Its mechanism further engages feedback mechanisms that regulate processes typically associated with heightened physiological responses. By influencing these internal feedback loops within targeted pathways, Микрозер affects the complex, multi-layered activation sequences that occur during specific physiological states. This action leads to a reduction in the concentration of circulating mediators and a net decrease in the intensity of downstream signaling within the target system, resulting in predictable system-level physiological modulation.

Dosage and Administration Information

The administration of Микрозер is structured exclusively as a long-term, oral course using available tablet strengths (8 mg, 16 mg, and 24 mg). The general principle of use involves taking the total daily dose in multiple divided administrations to maintain consistency, following standardized protocols.

Official Administration Protocols

The standard adult regimen requires a total daily dose ranging between 24 mg and 48 mg, which must not exceed the maximum daily dose of 48 mg. This dose is typically administered in two or three separate administrations throughout the day. To mitigate the possibility of mild gastric discomfort, the tablets are recommended to be taken with or immediately after meals.

Treatment with the medicine is typically a long-term commitment, as the full beneficial effect may only become apparent after consistent administration for several weeks or months. For dose adjustment, certain tablet strengths are scored to allow for precise titration by the prescriber.

Special Population Rules

Regarding specific populations, administration rules indicate that use in children and adolescents under 18 years is not recommended due to insufficient data on efficacy and safety in that age group. Conversely, no specific dose adjustment is typically required for older adults or patients with known hepatic or renal impairment. The entire protocol follows established standards to provide a consistent approach to usage.

Recent Clinical Evidence

Research Evidence / Overview of studies for Микрозер

Evidence for Use in Ménière's Disease

Research examining the active substance, Betahistine, has explored its use in conditions characterized by fluctuating or episodic manifestations, such as Ménière's disease. This evidence includes both Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. Studies monitored how patient-reported symptoms changed during the study periods. While numerous studies have explored this area, some large-scale RCTs did not report a statistically significant difference between the study substance and a placebo on the main outcome of vertigo attack frequency. Systematic reviews describe variability in findings across the historical research. Research describes group patterns; study results reflect the specific conditions under which they were conducted.

Study Focus: Vertigo Frequency and Functional Measures

Researchers in these trials focused on several key outcomes related to physical discomfort and functional imbalance. The primary focus was on measurements of vertigo attack frequency and the intensity or variability of individual episodes. Beyond tracking physical symptoms, researchers applied studies examining patient-reported experiences using standardized tools that assessed outcomes reflecting daily functioning or activity level.

Research in Peripheral Vestibular Vertigo

Betahistine was also studied for its use in a broader category of conditions known as peripheral vestibular vertigo. Research exploring short-term symptom changes in this area includes comparative trials and large-scale observational studies. Studies examined outcomes related to functional imbalance, primarily tracking patient-reported symptom scores, such as the overall level of dizziness or functional stability. Research exploring these issues often involves heterogeneous study populations, which is noted as a research limitation.

What Is Still Uncertain About Микрозер's Evidence

The existing research landscape is noted to have several limitations. Findings were mixed across the studies, and evidence quality varies across the trials that have been conducted. The long-term effects are not fully established, as follow-up durations were limited in pivotal trials. The results apply only to the populations studied; comparative evidence is lacking, and data for certain groups remain insufficient, especially for specific populations outside of the general adult demographic.

Key Studies & References

  1. Using betahistine in the treatment of patients with Menière's disease: a meta-analysis with the current randomized-controlled evidence

Frequently Asked Questions (FAQ)

Common questions about Микрозер (FAQ)

Q: Can I take Микрозер with over-the-counter pain relievers?

Official information indicates that common, non-interacting painkillers such as paracetamol can be taken to manage side effects like headache. However, other over-the-counter medicines, particularly those in the antihistamine class, have documented pharmacological conflicts with Микрозер. The official guidance emphasizes that all concurrent medications should be reviewed with a healthcare professional.


Q: Has Микрозер been approved by major health bodies like the FDA or EMA?

The medicine is widely approved and prescribed across many territories, including countries whose regulatory bodies align with the European Medicines Agency (EMA). It is described that the medication is not currently approved by the US Food and Drug Administration (FDA).


Q: Is there a maximum time someone can be on Микрозер?

Treatment with this medicine is intended for a long-term commitment, and many patients may take it for several months or even years. Official documentation does not define an absolute maximum duration, and the overall length of therapy is clinically determined based on the observed response to the medication.


Q: What happens if I take another medication that interacts with Микрозер?

An interaction between two medicines can alter how one or both drugs affect the body. Regulatory documents describe that a conflict may lead to a reduction in the intended effect of either medicine, or it could cause an increase in the systemic exposure of Микрозер, potentially raising the risk of side effects.


Q: Are there any known long-term side effects on the nervous system?

Common effects on the nervous system include headache. Regulatory summaries have noted that information on specific long-term effects that develop over many years is not fully established. Official guidance suggests that patients should report any persistent or new symptoms to their prescribing professional.


Q: What are the signs that Микрозер might not be working for me?

Because the full beneficial effect of the medicine takes time to build up, patients should not expect an immediate result. Official guidelines suggest that if no clear improvement in primary symptoms, such as the frequency or severity of spinning sensations (vertigo), is observed after the initial few months, the prescribing professional may need to reassess the treatment.


Q: Is it normal to feel unusually tired when starting Микрозер?

Official safety information lists tiredness and dizziness as possible common side effects. These effects may be more noticeable when a patient first begins taking the medication.


Q: Does Микрозер interact with alcohol consumption?

The medicine does not have a formal contraindication against alcohol consumption. However, official guidance suggests that caution may be warranted, as alcohol consumption has the potential to worsen certain side effects, such as dizziness or feeling tired.


Q: Is Микрозер available as a generic medication?

Yes. The active substance in this medicine is Betahistine, and it is widely available as a generic medication under various brand names in many countries.


Q: What happens if I forget to take a dose of Микрозер?

The regulatory guidance specifies that if a dose is forgotten, the missed dose should be skipped entirely, and the patient should proceed with the next scheduled dose. Regulatory protocol does not include taking a double dose to make up for a missed one.


Q: Does Микрозер affect blood pressure?

The medication is typically cautioned for use in patients who already have low blood pressure. Additionally, high plasma levels from an overdose have been associated with a potential drop in blood pressure, known as hypotension.


Q: Is Микрозер a controlled substance or known to be habit-forming?

According to official drug classification, this medicine is not considered to be addictive or habit-forming. It is also not classified as a controlled substance.


Q: Does Микрозер interact with common supplements like Vitamin D or Omega-3?

Official regulatory sources indicate there is insufficient information to confirm the safety or interaction profile of common nutritional supplements (including vitamins and Omega-3) when taken concurrently with this medicine.


Q: Is it necessary to have routine blood tests while taking Микрозер?

Regulatory documentation does not explicitly state a requirement for routine blood tests that are specifically necessary due to known chemical interference with laboratory results caused by the medicine itself.


Q: Can taking Микрозер affect my ability to drive or operate machinery?

The medication itself is generally regarded as having negligible effects on the ability to drive or use machinery. However, the condition being treated and potential side effects like dizziness and tiredness may temporarily impair these abilities. Caution is warranted until an individual is familiar with their reaction to the medication.


Q: Can men or women taking Микрозер experience issues with fertility?

Regulatory documents include findings from animal studies which demonstrated no direct effects on fertility. Specific data regarding the medicine's impact on human fertility is not typically detailed in the official product information.


Q: Is it necessary to finish the entire course of Микрозер even if symptoms improve?

The official protocol is that treatment is intended to be continued as prescribed. Decisions to change the course, including stopping or reducing the amount, are matters to be discussed only with a healthcare professional.


Q: Are there any known interactions between Микрозер and herbal teas?

Regulatory documents confirm there is insufficient information from official sources to definitively confirm the safety or interaction profile of herbal remedies or teas when taken alongside this medication.


Q: What is the half-life of Микрозер?

The biological half-life of the primary metabolite, which is the substance measured in the body, is described in pharmacokinetic data as approximately 3.5 hours.


Q: Can Микрозер cause skin rashes or sensitivity to the sun?

Known adverse reactions include skin rashes, such as urticaria (hives) and pruritus (itching). Official safety lists do not document sensitivity to the sun (photosensitivity) as a reported side effect.


Q: Does Микрозер affect sleep patterns or cause insomnia?

Yes, difficulty sleeping or insomnia is listed in the official documents as a possible side effect of the medicine.


Q: Is it common to experience dizziness or lightheadedness on Микрозер?

Official documents list dizziness as a common side effect. It is important to remember that dizziness is also a primary symptom of the condition the medicine is intended to treat.

How should Микрозер be stored and disposed of?

The storage and disposal of Микрозер (Betahistine) tablets must adhere strictly to official regulatory requirements to maintain product stability and safety.

Official Storage Conditions

Requirement Details
Temperature Limit Do not store the medicine above mathbf30 C.
Protection Store in a cool, dry place; keep the tablets in the original pack to protect them from moisture.
Safety The product must be kept out of the sight and reach of children.
Stability The medicine has a declared 3-year shelf-life when stored under the recommended conditions.

Disposal Instructions

Unused or expired Микрозер must be handled according to specific rules. The tablets should be returned to a pharmacy for proper disposal. It is explicitly required that the product must not be emptied into household drains, the sewer, or any body of water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Микрозер found in:

A-Z Index: